CN104507928B - 脂质合成的杂环调节剂 - Google Patents

脂质合成的杂环调节剂 Download PDF

Info

Publication number
CN104507928B
CN104507928B CN201380035602.4A CN201380035602A CN104507928B CN 104507928 B CN104507928 B CN 104507928B CN 201380035602 A CN201380035602 A CN 201380035602A CN 104507928 B CN104507928 B CN 104507928B
Authority
CN
China
Prior art keywords
alkyl
compound
compound according
halogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380035602.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104507928A (zh
Inventor
J·D·奥斯洛布
R·S·麦克道尔
R·约翰逊
H·杨
M·伊万奇克
C·A·扎哈里亚
H·蔡
L·W·胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ganglai Pharmaceutical Co ltd
Sagimit Biosciences
Original Assignee
3V Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48790663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104507928(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3V Biosciences Inc filed Critical 3V Biosciences Inc
Publication of CN104507928A publication Critical patent/CN104507928A/zh
Application granted granted Critical
Publication of CN104507928B publication Critical patent/CN104507928B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380035602.4A 2012-07-03 2013-07-01 脂质合成的杂环调节剂 Active CN104507928B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261667894P 2012-07-03 2012-07-03
US61/667,894 2012-07-03
US201261698511P 2012-09-07 2012-09-07
US61/698,511 2012-09-07
US201261699819P 2012-09-11 2012-09-11
US61/699,819 2012-09-11
US201361785933P 2013-03-14 2013-03-14
US61/785,933 2013-03-14
PCT/US2013/048950 WO2014008197A1 (en) 2012-07-03 2013-07-01 Heterocyclic modulators of lipid synthesis

Publications (2)

Publication Number Publication Date
CN104507928A CN104507928A (zh) 2015-04-08
CN104507928B true CN104507928B (zh) 2016-09-28

Family

ID=48790663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035602.4A Active CN104507928B (zh) 2012-07-03 2013-07-01 脂质合成的杂环调节剂

Country Status (17)

Country Link
US (3) US9428502B2 (enExample)
EP (1) EP2870150B1 (enExample)
JP (1) JP6109934B2 (enExample)
KR (1) KR102071095B1 (enExample)
CN (1) CN104507928B (enExample)
AU (2) AU2013286894B2 (enExample)
BR (1) BR112015000106B1 (enExample)
CA (1) CA2877999C (enExample)
ES (1) ES2738823T3 (enExample)
IL (1) IL236407A (enExample)
IN (1) IN2015DN00137A (enExample)
MX (1) MX364815B (enExample)
NZ (2) NZ729443A (enExample)
PL (1) PL2870150T3 (enExample)
SG (1) SG11201500024YA (enExample)
WO (1) WO2014008197A1 (enExample)
ZA (1) ZA201409477B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170119786A1 (en) 2011-03-08 2017-05-04 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9624173B2 (en) * 2011-03-08 2017-04-18 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
TWI522348B (zh) * 2011-03-08 2016-02-21 ３ Ｖ生物科技公司 脂質合成之雜環調節劑
KR102071095B1 (ko) * 2012-07-03 2020-01-29 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
CA2934251C (en) * 2013-12-20 2024-01-02 3-V Biosciences, Inc. A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
JP6522007B2 (ja) * 2014-01-07 2019-05-29 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 癌及びウイルス感染症に対する使用のための脂質合成の複素環式モジュレータ
ES2833454T3 (es) * 2014-08-15 2021-06-15 Sagimet Biosciences Inc Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
JP6758314B2 (ja) * 2015-03-19 2020-09-23 サギメット バイオサイエンシーズ インコーポレイテッド 脂質合成の複素環式調節因子
JP2018083758A (ja) * 2015-03-25 2018-05-31 旭硝子株式会社 ピラゾール誘導体の製造方法
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PE20180572A1 (es) 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
US11753626B2 (en) 2016-03-09 2023-09-12 Beijing Percans Oncology Co., Ltd. Tumor cell suspension cultures and related methods
KR102644934B1 (ko) * 2016-11-11 2024-03-08 새지메트 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
US20220340556A1 (en) * 2016-11-11 2022-10-27 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis
CN107954852A (zh) * 2017-11-30 2018-04-24 贝利化学（张家港）有限公司 2，5-二卤代苯甲酸的制备方法
US12398155B2 (en) 2018-12-26 2025-08-26 Janssen Pharmaceutica Nv Thienopyridinone compounds
US12628858B2 (en) * 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
CN111592495A (zh) * 2020-07-06 2020-08-28 上海启讯医药科技有限公司 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法
CN116482278B (zh) * 2023-05-06 2024-02-09 广州清瑞生物科技有限责任公司 一种用于检测阿昔洛韦的对照品的制备方法
CN119080742A (zh) * 2023-06-05 2024-12-06 甘莱制药有限公司 脂质合成的杂环调节剂的工业化制备
WO2025086054A1 (zh) * 2023-10-23 2025-05-01 歌礼生物科技（杭州）有限公司 一种包含苯甲腈衍生物的药物组合物
AU2024395542A1 (en) 2023-12-07 2026-05-28 Böse Pharmaceuticals Ab Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
WO2008075077A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
US20090105305A1 (en) * 2006-12-21 2009-04-23 Astrazeneca Ab Therapeutic Agents - 550
US20090118332A1 (en) * 2006-12-21 2009-05-07 Astrazeneca Ab Therapeutic Agents - 551

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006011363D1 (de) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
US9624173B2 (en) * 2011-03-08 2017-04-18 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US20170119786A1 (en) * 2011-03-08 2017-05-04 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
LT2683244T (lt) 2011-03-08 2017-04-10 3-V Biosciences, Inc. Lipidų sintezės heterocikliniai moduliatoriai
TWI522348B (zh) * 2011-03-08 2016-02-21 ３ Ｖ生物科技公司 脂質合成之雜環調節劑
KR102071095B1 (ko) * 2012-07-03 2020-01-29 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
CA2934251C (en) * 2013-12-20 2024-01-02 3-V Biosciences, Inc. A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
JP6522007B2 (ja) * 2014-01-07 2019-05-29 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 癌及びウイルス感染症に対する使用のための脂質合成の複素環式モジュレータ
ES2833454T3 (es) * 2014-08-15 2021-06-15 Sagimet Biosciences Inc Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente
JP6758314B2 (ja) * 2015-03-19 2020-09-23 サギメット バイオサイエンシーズ インコーポレイテッド 脂質合成の複素環式調節因子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
WO2008075077A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
US20090105305A1 (en) * 2006-12-21 2009-04-23 Astrazeneca Ab Therapeutic Agents - 550
US20090118332A1 (en) * 2006-12-21 2009-05-07 Astrazeneca Ab Therapeutic Agents - 551

Also Published As

Publication number Publication date
PL2870150T3 (pl) 2019-12-31
IN2015DN00137A (enExample) 2015-06-12
US20180222892A1 (en) 2018-08-09
AU2013286894B2 (en) 2017-12-07
KR20150032571A (ko) 2015-03-26
JP6109934B2 (ja) 2017-04-05
SG11201500024YA (en) 2015-03-30
AU2013286894A1 (en) 2015-01-22
JP2015522036A (ja) 2015-08-03
US9428502B2 (en) 2016-08-30
CA2877999A1 (en) 2014-01-09
US20160311803A1 (en) 2016-10-27
US10053450B2 (en) 2018-08-21
EP2870150B1 (en) 2019-06-19
CN104507928A (zh) 2015-04-08
NZ729443A (en) 2017-11-24
US20150210688A1 (en) 2015-07-30
AU2017265027A1 (en) 2017-12-14
US10118913B2 (en) 2018-11-06
ES2738823T3 (es) 2020-01-27
MX364815B (es) 2019-05-08
CA2877999C (en) 2021-02-23
KR102071095B1 (ko) 2020-01-29
EP2870150A1 (en) 2015-05-13
IL236407A (en) 2017-10-31
BR112015000106B1 (pt) 2022-02-22
ZA201409477B (en) 2021-05-26
RU2015103345A (ru) 2016-08-20
IL236407A0 (en) 2015-02-26
HK1208445A1 (en) 2016-03-04
WO2014008197A1 (en) 2014-01-09
BR112015000106A2 (pt) 2017-06-27
NZ703162A (en) 2017-05-26
MX2015000151A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
CN104507928A (zh) 脂质合成的杂环调节剂
JP7104232B2 (ja) 芳香族スルホンアミド誘導体
EP3083583B1 (en) Heterocyclic modulators of lipid synthesis and combinations thereof
KR102627266B1 (ko) 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
AU2018360577A1 (en) Bridged bicyclic compounds as farnesoid X receptor modulators
CN110234650A (zh) 芳基烃受体(AhR)调节剂化合物
CN107849053B (zh) 螺环化合物
CN108473497A (zh) Ep4拮抗剂
CN110191884A (zh) 取代的6-(1h-吡唑-1-基)嘧啶-4-胺衍生物及其用途
RU2779069C2 (ru) Гетероциклические модуляторы синтеза липидов
WO2025214476A1 (zh) Cbl-b抑制剂
HK1208445B (en) Heterocyclic modulators of lipid synthesis
CA3022793C (en) Aromatic sulfonamide derivatives
HK40079881A (en) Aromatic sulfonamide derivatives
HK40079881B (en) Aromatic sulfonamide derivatives
HK40111682A (en) New heterocyclic compounds
HK1208455A1 (en) Triazole compounds as antivirals

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Sagimit Biosciences

Address before: California, USA

Patentee before: 3-V Biosciences, Inc.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20191212

Address after: Floor 3, No. 665, Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Ganglai Pharmaceutical Co.,Ltd.

Address before: California, USA

Patentee before: Sagimit Biosciences

TR01 Transfer of patent right